You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Dow
Merck
Baxter
Moodys
Colorcon
Medtronic

Last Updated: February 23, 2024

HEMANGEOL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Hemangeol, and what generic alternatives are available?

Hemangeol is a drug marketed by Pierre Fabre Derma and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has forty-seven patent family members in thirty-one countries.

The generic ingredient in HEMANGEOL is propranolol hydrochloride. There are twenty-two drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the propranolol hydrochloride profile page.

Drug patent expirations by year for HEMANGEOL
Drug Prices for HEMANGEOL

See drug prices for HEMANGEOL

Recent Clinical Trials for HEMANGEOL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Christiana Care Health ServicesPhase 1
Columbia UniversityPhase 2
University of Missouri-ColumbiaEarly Phase 1

See all HEMANGEOL clinical trials

Pharmacology for HEMANGEOL
Paragraph IV (Patent) Challenges for HEMANGEOL
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
HEMANGEOL Oral Solution propranolol hydrochloride 4.28 mg/mL 205410 1 2022-07-21

US Patents and Regulatory Information for HEMANGEOL

HEMANGEOL is protected by two US patents.

Patents protecting HEMANGEOL

Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: METHOD TO TREAT HEMANGIOMA.

Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: METHOD TO TREAT INFANTILE HEMANGIOMA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pierre Fabre Derma HEMANGEOL propranolol hydrochloride SOLUTION;ORAL 205410-001 Mar 14, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Pierre Fabre Derma HEMANGEOL propranolol hydrochloride SOLUTION;ORAL 205410-001 Mar 14, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for HEMANGEOL

See the table below for patents covering HEMANGEOL around the world.

Country Patent Number Title Estimated Expiration
Japan 2011500661 ⤷  Try a Trial
Brazil PI0816536 uso de um beta bloqueador ⤷  Try a Trial
Russian Federation 2010112816 ПРИМЕНЕНИЕ БЛОКА-БЛОКАТОРА ДЛЯ ИЗГОТОВЛЕНИЯ ЛЕКАРСТВЕННОГО СРЕДСТВА ДЛЯ ЛЕЧЕНИЯ ГЕМАНГИОМ ⤷  Try a Trial
Croatia P20120765 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
McKesson
Harvard Business School
AstraZeneca
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.